Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096866421> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W3096866421 endingPage "S26" @default.
- W3096866421 startingPage "S26" @default.
- W3096866421 abstract "The global PIONEER program investigated the efficacy and safety of oral semaglutide, a glucagon-like peptide-1 receptor agonist. Patients with type 2 diabetes were randomized to once-daily oral semaglutide (3, 7 or 14 mg, or flexibly dosed [flex]), placebo or active comparator (empagliflozin 25 mg, sitagliptin 100 mg or liraglutide 1.8 mg). This exploratory subgroup analysis evaluated the effect of race on glycated hemoglobin (HbA1c) and body weight (BW) reductions at the end of treatment (week 26, 52 or 78). Data were analyzed from PIONEER 1–4, 7 and 8 by race (White, Asian, Black/African American). Baseline characteristics were generally similar across subgroups except for BW, which was lower in Asian patients. Generally, greater HbA1c reductions were observed with oral semaglutide 14 mg/flex vs comparators across subgroups (Table). In PIONEER 1, 4 and 8, there was a significant interaction between treatment and race, with greater HbA1c reductions and estimated treatment differences in Asian patients than in other subgroups (Table). Overall, BW reductions were greater for oral semaglutide vs comparators, regardless of subgroup and without significant interactions between treatment and race. Our findings in this exploratory subgroup analysis suggest that, in some PIONEER trials, Asian patients achieve greater HbA1c reductions than other race groups when treated with oral semaglutide." @default.
- W3096866421 created "2020-11-09" @default.
- W3096866421 creator A5005307199 @default.
- W3096866421 creator A5031060251 @default.
- W3096866421 creator A5037124337 @default.
- W3096866421 creator A5068409224 @default.
- W3096866421 creator A5068563768 @default.
- W3096866421 creator A5077027153 @default.
- W3096866421 date "2020-10-01" @default.
- W3096866421 modified "2023-09-23" @default.
- W3096866421 title "60 - Efficacy of Oral Semaglutide According to Race: An Exploratory Subgroup Analysis of the PIONEER Trial Program" @default.
- W3096866421 doi "https://doi.org/10.1016/j.jcjd.2020.08.066" @default.
- W3096866421 hasPublicationYear "2020" @default.
- W3096866421 type Work @default.
- W3096866421 sameAs 3096866421 @default.
- W3096866421 citedByCount "0" @default.
- W3096866421 crossrefType "journal-article" @default.
- W3096866421 hasAuthorship W3096866421A5005307199 @default.
- W3096866421 hasAuthorship W3096866421A5031060251 @default.
- W3096866421 hasAuthorship W3096866421A5037124337 @default.
- W3096866421 hasAuthorship W3096866421A5068409224 @default.
- W3096866421 hasAuthorship W3096866421A5068563768 @default.
- W3096866421 hasAuthorship W3096866421A5077027153 @default.
- W3096866421 hasConcept C126322002 @default.
- W3096866421 hasConcept C134018914 @default.
- W3096866421 hasConcept C142724271 @default.
- W3096866421 hasConcept C187960798 @default.
- W3096866421 hasConcept C204787440 @default.
- W3096866421 hasConcept C27081682 @default.
- W3096866421 hasConcept C2777180221 @default.
- W3096866421 hasConcept C2777538456 @default.
- W3096866421 hasConcept C2779284873 @default.
- W3096866421 hasConcept C2781308992 @default.
- W3096866421 hasConcept C2909862629 @default.
- W3096866421 hasConcept C44249647 @default.
- W3096866421 hasConcept C555293320 @default.
- W3096866421 hasConcept C71924100 @default.
- W3096866421 hasConceptScore W3096866421C126322002 @default.
- W3096866421 hasConceptScore W3096866421C134018914 @default.
- W3096866421 hasConceptScore W3096866421C142724271 @default.
- W3096866421 hasConceptScore W3096866421C187960798 @default.
- W3096866421 hasConceptScore W3096866421C204787440 @default.
- W3096866421 hasConceptScore W3096866421C27081682 @default.
- W3096866421 hasConceptScore W3096866421C2777180221 @default.
- W3096866421 hasConceptScore W3096866421C2777538456 @default.
- W3096866421 hasConceptScore W3096866421C2779284873 @default.
- W3096866421 hasConceptScore W3096866421C2781308992 @default.
- W3096866421 hasConceptScore W3096866421C2909862629 @default.
- W3096866421 hasConceptScore W3096866421C44249647 @default.
- W3096866421 hasConceptScore W3096866421C555293320 @default.
- W3096866421 hasConceptScore W3096866421C71924100 @default.
- W3096866421 hasIssue "7" @default.
- W3096866421 hasLocation W30968664211 @default.
- W3096866421 hasOpenAccess W3096866421 @default.
- W3096866421 hasPrimaryLocation W30968664211 @default.
- W3096866421 hasRelatedWork W1976618350 @default.
- W3096866421 hasRelatedWork W2485192471 @default.
- W3096866421 hasRelatedWork W2525452711 @default.
- W3096866421 hasRelatedWork W2567011734 @default.
- W3096866421 hasRelatedWork W2807279220 @default.
- W3096866421 hasRelatedWork W2884645397 @default.
- W3096866421 hasRelatedWork W2904771920 @default.
- W3096866421 hasRelatedWork W2922550132 @default.
- W3096866421 hasRelatedWork W3031406596 @default.
- W3096866421 hasRelatedWork W3066769783 @default.
- W3096866421 hasVolume "44" @default.
- W3096866421 isParatext "false" @default.
- W3096866421 isRetracted "false" @default.
- W3096866421 magId "3096866421" @default.
- W3096866421 workType "article" @default.